Cargando…

Validating the Use of Corifollitropin Alfa in Progestin-Primed Ovarian Stimulation Protocol on Normal and High Responders by Comparing with Conventional Antagonist Protocol: A Retrospective Study

Our previous study showed a satisfactory reproductive outcome resulting from the patient-friendly ovarian stimulation protocol using long-acting follicle stimulation hormone (FSH) plus oral medroxyprogesterone acetate (MPA). The present retrospective study aims to compare the efficacy of the patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Chen-Yu, Chen, Guan-Yeu, Shieh, Miawh-Lirng, Li, Hsin-Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7344689/
https://www.ncbi.nlm.nih.gov/pubmed/32575849
http://dx.doi.org/10.3390/life10060090
_version_ 1783556003166420992
author Huang, Chen-Yu
Chen, Guan-Yeu
Shieh, Miawh-Lirng
Li, Hsin-Yang
author_facet Huang, Chen-Yu
Chen, Guan-Yeu
Shieh, Miawh-Lirng
Li, Hsin-Yang
author_sort Huang, Chen-Yu
collection PubMed
description Our previous study showed a satisfactory reproductive outcome resulting from the patient-friendly ovarian stimulation protocol using long-acting follicle stimulation hormone (FSH) plus oral medroxyprogesterone acetate (MPA). The present retrospective study aims to compare the efficacy of the patient-friendly ovarian stimulation protocol with that of the antagonist protocol on normal and high responders aged between 24 and 39 years in a tertiary fertility center in Taiwan. To prevent premature luteinizing hormone (LH) surge, oral MPA was given to patients in group 1 (n = 57), whereas antagonist protocol was applied to group 2 (n = 53). Duration and dosage of stimulation, number of injections and visits before trigger, incidence of premature LH surge, number of oocytes retrieved, fertilization rate, cleavage rate, rate of good embryos available, incidence of ovarian hyperstimulation syndrome, cumulative clinical pregnancy rate and live birth rate per retrieval were compared between groups. We conclude that our patient-friendly ovarian stimulation protocol with MPA demonstrates satisfactory stimulation and reproductive outcomes that are comparable to those of an antagonist protocol.
format Online
Article
Text
id pubmed-7344689
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73446892020-07-09 Validating the Use of Corifollitropin Alfa in Progestin-Primed Ovarian Stimulation Protocol on Normal and High Responders by Comparing with Conventional Antagonist Protocol: A Retrospective Study Huang, Chen-Yu Chen, Guan-Yeu Shieh, Miawh-Lirng Li, Hsin-Yang Life (Basel) Article Our previous study showed a satisfactory reproductive outcome resulting from the patient-friendly ovarian stimulation protocol using long-acting follicle stimulation hormone (FSH) plus oral medroxyprogesterone acetate (MPA). The present retrospective study aims to compare the efficacy of the patient-friendly ovarian stimulation protocol with that of the antagonist protocol on normal and high responders aged between 24 and 39 years in a tertiary fertility center in Taiwan. To prevent premature luteinizing hormone (LH) surge, oral MPA was given to patients in group 1 (n = 57), whereas antagonist protocol was applied to group 2 (n = 53). Duration and dosage of stimulation, number of injections and visits before trigger, incidence of premature LH surge, number of oocytes retrieved, fertilization rate, cleavage rate, rate of good embryos available, incidence of ovarian hyperstimulation syndrome, cumulative clinical pregnancy rate and live birth rate per retrieval were compared between groups. We conclude that our patient-friendly ovarian stimulation protocol with MPA demonstrates satisfactory stimulation and reproductive outcomes that are comparable to those of an antagonist protocol. MDPI 2020-06-21 /pmc/articles/PMC7344689/ /pubmed/32575849 http://dx.doi.org/10.3390/life10060090 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Huang, Chen-Yu
Chen, Guan-Yeu
Shieh, Miawh-Lirng
Li, Hsin-Yang
Validating the Use of Corifollitropin Alfa in Progestin-Primed Ovarian Stimulation Protocol on Normal and High Responders by Comparing with Conventional Antagonist Protocol: A Retrospective Study
title Validating the Use of Corifollitropin Alfa in Progestin-Primed Ovarian Stimulation Protocol on Normal and High Responders by Comparing with Conventional Antagonist Protocol: A Retrospective Study
title_full Validating the Use of Corifollitropin Alfa in Progestin-Primed Ovarian Stimulation Protocol on Normal and High Responders by Comparing with Conventional Antagonist Protocol: A Retrospective Study
title_fullStr Validating the Use of Corifollitropin Alfa in Progestin-Primed Ovarian Stimulation Protocol on Normal and High Responders by Comparing with Conventional Antagonist Protocol: A Retrospective Study
title_full_unstemmed Validating the Use of Corifollitropin Alfa in Progestin-Primed Ovarian Stimulation Protocol on Normal and High Responders by Comparing with Conventional Antagonist Protocol: A Retrospective Study
title_short Validating the Use of Corifollitropin Alfa in Progestin-Primed Ovarian Stimulation Protocol on Normal and High Responders by Comparing with Conventional Antagonist Protocol: A Retrospective Study
title_sort validating the use of corifollitropin alfa in progestin-primed ovarian stimulation protocol on normal and high responders by comparing with conventional antagonist protocol: a retrospective study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7344689/
https://www.ncbi.nlm.nih.gov/pubmed/32575849
http://dx.doi.org/10.3390/life10060090
work_keys_str_mv AT huangchenyu validatingtheuseofcorifollitropinalfainprogestinprimedovarianstimulationprotocolonnormalandhighrespondersbycomparingwithconventionalantagonistprotocolaretrospectivestudy
AT chenguanyeu validatingtheuseofcorifollitropinalfainprogestinprimedovarianstimulationprotocolonnormalandhighrespondersbycomparingwithconventionalantagonistprotocolaretrospectivestudy
AT shiehmiawhlirng validatingtheuseofcorifollitropinalfainprogestinprimedovarianstimulationprotocolonnormalandhighrespondersbycomparingwithconventionalantagonistprotocolaretrospectivestudy
AT lihsinyang validatingtheuseofcorifollitropinalfainprogestinprimedovarianstimulationprotocolonnormalandhighrespondersbycomparingwithconventionalantagonistprotocolaretrospectivestudy